Septerna (NASDAQ:SEPN) Trading 5.7% Higher – Should You Buy?

Septerna, Inc. (NASDAQ:SEPN)’s stock price shot up 5.7% during mid-day trading on Wednesday . The company traded as high as $19.39 and last traded at $19.76. 31,567 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 193,123 shares. The stock had previously closed at $18.70.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on SEPN. JPMorgan Chase & Co. initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price for the company. Wells Fargo & Company initiated coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective on the stock. Cantor Fitzgerald began coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $50.00 price target for the company. Finally, TD Cowen started coverage on Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating for the company.

Septerna Trading Up 0.5 %

The firm has a fifty day simple moving average of $22.41.

Insider Buying and Selling

In related news, major shareholder Rock Ventures V. L.P. Third bought 370,500 shares of the business’s stock in a transaction on Monday, October 28th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the completion of the purchase, the insider now owns 6,215,591 shares of the company’s stock, valued at $111,880,638. This represents a 6.34 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Institutional Trading of Septerna

An institutional investor recently bought a new position in Septerna stock. SG Americas Securities LLC purchased a new position in Septerna, Inc. (NASDAQ:SEPN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,095 shares of the company’s stock, valued at approximately $185,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.